Close menu




April 9th, 2024 | 06:45 CEST

Palantir, Globex Mining, Bayer - The trend is pointing upwards

  • Mining
  • Commodities
  • Gold
  • Silver
  • Pharma
  • Software
Photo credits: pixabay.com

After a successful first quarter of 2024, the DAX and Dow Jones took a well-deserved breather last week. In contrast, the precious metal markets for gold and silver continued their upward trend. Gold also reached new absolute highs of USD 2,354 per ounce. While gold producers such as Barrick Gold and Newmont remained in hibernation, they have been following the rising base price for several weeks now. There is currently also an opportunity for smaller commodity stocks to participate disproportionately in the upward trend.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: PALANTIR TECHNOLOGIES INC | US69608A1088 , GLOBEX MINING ENTPRS INC. | CA3799005093 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    Globex Mining - Asset classes with buy signals

    CEO Jack Stoch has been at the helm of the commodities incubator Globex Mining since 1983, focusing on acquiring and optioning properties to partners. Since then, a diversified portfolio of 247 projects has been built up. This includes interests in 123 precious metals, 68 base metals and 56 specialty metals and industrial minerals.

    The gold and silver projects, in particular, are likely to significantly increase the intrinsic value due to the exploding underlying values. If one considers the market capitalization of CAD 51.39 million and subtracts the portfolio of cash, shares and marketable securities of more than CAD 25 million, the value of the almost 250 holdings would be around CAD 26 million. The portfolio's undervaluation is obvious at first glance.

    In addition, Globex Mining receives a regular cash flow through income from license fees, the leasing of mining rights and the pro rata collection of minerals sold by partners. The Company is currently cooperating with around 100 projects with such licensees, who also bear the exploration costs.

    In addition to rising gold and silver prices, the tide is also turning for industrial metals. The copper chart has been pointing upwards for weeks, and metals such as lithium, which are urgently needed for the energy transition, are also currently forming a stable base. The Globex share chart reflects the positive portfolio development. At CAD 0.93, the share price is on the verge of breaking out of an ascending triangle. If this succeeds, the stock should quickly leave the penny stock zone.

    Palantir - Before the next move

    The technical chart development of data analysis specialist Palantir is almost textbook-like. Since the beginning of May last year, the Company's market capitalization rose by around 280% from USD 7.28 to USD 27.50, partly due to the boom in the trending topic of artificial intelligence. The Palantir share has since corrected and further reduced the overbought conditions created by the price jump. A prominent support zone, the annual high of USD 21.85 reached in 2023, has been successfully defended so far.

    The new cooperation agreement with Oracle could result in a push in the share price. The two US companies intend to collaborate on the sale of cloud and AI services, which should once again significantly increase the revenue and profit of the Denver, Colorado-based company.

    One analyst who was not surprised by Palantir's recent rally is Bruce Kamich from TheStreet Pro. Following the Oracle deal, he set a new price target of USD 48. This would mean a potential upside of around 120% on the current share price.

    Bayer - A drop in the ocean

    Despite the positive news over the weekend, the suffering continues for investors of the pharmaceutical and agricultural giant. Nevertheless, the Leverkusen-based company reported a partial success in a legal dispute, which once again concerned the weedkiller Roundup.

    According to court documents filed on Friday, Judge Daniel Green in Jefferson City, Missouri, reduced the damages awarded to the three plaintiffs by a jury from USD 1.5 billion to USD 600 million. Bayer had lost the case against the three plaintiffs in November. The plaintiffs claimed that the long-term use of the weedkiller caused their cancer.

    However, as revealed in the published annual report for the year 2023, this was just one of approximately 54,000 lawsuits related to the weedkiller glyphosate. Thus, the Company is far from resolving this ongoing issue. Accordingly, Bayer shares were only able to recover briefly, but they gave up all their gains again yesterday and were once again at the bottom of the DAX, down 4%. A turnaround looks different!


    The intrinsic value of Globex Mining's portfolio is likely to have developed positively due to the sharp rise in precious metal prices. Meanwhile, analysts see a doubling of the Palantir share price. Bayer celebrated a partial success, but the glyphosate lawsuits will likely continue to weigh on the Company.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST

    BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?

    • Biotechnology
    • Biotech
    • Pharma

    On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.

    Read

    Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST

    BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions

    • Biotechnology
    • Pharma
    • Biotech

    Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.

    Read

    Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST

    70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!

    • Mining
    • Tungsten
    • hightech
    • chemicals
    • Biotechnology

    Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?

    Read